Status:
RECRUITING
Natural History of Type 1 Interferonopathies: Insights From a European Cohort
Lead Sponsor:
Imagine Institute
Conditions:
Genetic Disease
Immune Dysfunction
Eligibility:
All Genders
Brief Summary
Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosup...
Eligibility Criteria
Inclusion Criteria:
- Genetically confirmed patient with type I interferonopathy
- Patient affiliated to a social security scheme or beneficiary of such a scheme.
Exclusion Criteria:
- Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2045
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT07040774
Start Date
October 1 2025
End Date
October 1 2045
Last Update
February 13 2026
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University Innsbruck
Innsbruck, Austria
2
Antwerp University Hospital
Antwerp, Belgium
3
Children's Hospital Zagreb
Zagreb, Croatia
4
Motol University Hospital
Prague, Czechia